Antifungal activity of a new triazole, voriconazole (UK-109496), against clinical isolates of Aspergillus spp.

Journal of Infection and Chemotherapy

Volumn 6, Issue 2, 2000, Pages 101-103

  Maesaki, Shigefumi ^a   Iwakawa, Jun ^a   Higashiyama, Yasuhito ^a   Miyazaki, Yoshitsugu ^a   Yanagihara, Katsunori ^a   Tomono, Kazunori ^a   Tashiro, Takayoshi ^a   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

Alamar blue; Antifungal agents; Aspergillus; MIC; Voriconazole

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; CONTROLLED STUDY; DRUG POTENCY; MINIMUM INHIBITORY CONCENTRATION; MOULD; NONHUMAN; SPECIES DIFFERENCE; STRAIN DIFFERENCE; YEAST;

EID: 0033928087     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00012145     Document Type: Article

References (12)

1. Johnson EM, Szekely A, Warnock DW. In vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 1998;42:741-5.
2. Cuenca-Estrella M, Rodriguez Tudela JL, Mellado E, Martinez Suarez JV, Monzon A. Comparison of the in-vitro activity of voriconazole (UK-109496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 1998;42:531-3.
3. McGinnis MR, Pasarell L, Sutton DA, Fothergill AW, Cooper CJ, Rinaldi MG. In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob Agents Chemother 1997;41: 1832-4.
4. Ruhnke M, Schmidt WA, Trautmann M. In vitro activities of voriconazole (UK-109496) against fiuconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1997;41:575-7.
5. Martin MV, Yates J, Hitchcock CA. Comparison of voriconazole (UK-109496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother 1997;41:13-6.
6. Murphy M, Bernard EM, Ishimaru T, Armstrong D. Activity of voriconazole (UK-109496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 1997;41: 696-8.
7. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27-A. Wayne, PA: NCCLS; 1997.
8. Espinel-Ingroff A, Bartlett M, Bowden R, Chin NX, Cooper CJ, Fothergill, et al. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol 1997;35:139-13.
9. Jahn B, Stuben A, Bhakdi S. Colorimetric susceptibility testing for Aspergillus fuminigatus: comparison of menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide and alamar blue tests. J Clin Microbiol 1996;34:2039-41.
10. Matsuda H, Kohno S, Maesaki S, Yamada H, Koga H, Tamura M, et al. Application of ubiquinone systems and electrophoretic comparison of enzymes to identification of clinical isolates of Aspergillus fumigatus and several other species of Aspergillus. J Clin Microbiol 1992;30:1999-2005.
11. Radford SA, Johnson EM, Warnock DW. In vitro studies of activity of voriconazole (UK-109496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother 1997;41:841-3.
12. Maesaki S, Kohno S, Kaku M, Koga H, Hara K. Effects of antifungal agent combinations administered simultaneously and sequentially against Aspergillus fumigatus. Antimicrob Agents Chemother 1994;38:2843-5.